15th Biosimilars Congregation 2021 (Virtual Conference) 2021

15th Biosimilars Congregation 2021 (Virtual Conference) 2021

15th Biosimilars Congregation 2021

23rd - 24th June 2021, Virtual Conference (Time Zone - BST)

Our 15thBiosimilars Congregation 2021 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies, our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe, Biosimilar products to the market place. By attending this conference, you will gain a comprehensive outlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

DELEGATE REGISTRATION:

Email: kavitha@virtueinsight.co.in  or Call: +44-20 3509 3779

Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer.

EARLY BIRD PRICE

1 Delegate @ £300 +VAT (Valid Till 17th May 2021)

3 Delegates @ £700 +VAT (Valid Till 17th May 2021)

STANDARD PRICE

1 Delegate @ £500 +VAT (Valid From 18th May 2021)

3 Delegates @ £1200 +VAT (Valid From 18th May 2021)

Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to kavitha@virtueinsight.co.in

KEY SPEAKERS:

• FREDRIK SUNDBERG, Global Director, Strategic Technology Partnership, Cytiva (Formerly GE Life Sciences)
• RAJESH DESIKAN, Vice President & Head, US Marketing, Oncology & Immunology Biosimilars, Fresenius-Kabi
• JULIE MARECHAL JAMIL, Director Biosimilar Policy & Science, Medicines for Europe
• MATTHEW TURNER, Senior Director Government Affairs and Policy Biosimilars Europe, Asia, Latam & Canada, Fresenius Kabi
• CECIL NICK, Vice President, Parexel
• ANNA AILLERIE, Brand Management Lead, Europe, Dr Reddy’s Laboratories SA
• MIGUEL NAVARRETE OLMEDO, Hospital & Biosimilars Commercial Director, STADA Arzneimittel
• LOUIS BOON, CSO, Polpharma Biologics
• HANMANT BARKATE, Vice President & Head Medical Services (India, MEA), Glenmark
• SWEETY MATHEW, Regulatory Affairs, Biocon
• MARTA BALDRIGHI, Policy & Science Officer, Medicines for Europe
• NIKLAS EKMAN, Head of the Biological Section, Finnish Medicines Agency
• OMAR ALI, Pharmacist Consultant, QIPP Adviser Payer Network
• RENE ANOUR, Senior Clinical Expert/Head of National Scientific Advice, Austrian Medicines & Medical Devices Agency (AGES)
• BER OOMEN, Executive Director, ESNO (European Specialist Nurses Organisations)
• MICHEL MIKHAIL, International Expert in Biosimilars, Global Expert in Regulatory Affairs, Michel Mikhail
• LENNEKE DE WINTER, Senior Scientist USP, Polpharma Biologics
• JAAP WIELING, CSO, BiosanaPharma
• JAKOB LANGE, Senior Director Delivery Systems, Ypsomed
• ANDREAU SOLDEVILA, Founder and CEO, Syna Therapeutics
• INGRID SCHWARZENBERGER, Senior Regulatory Consultant, Independent Consultant
• BERT THOMAS, Senior Vice President, Business Development, Bio-Thera Solutions
• SANDY EISEN, Chief Medical Officer, Frontline Pharma Consulting Ltd
• ZIQUN HAN, Director, Zen Medical Science
• MARIE MANLEY, Partner, Head of the UK Life Sciences, Sidley Austin
• ALEXANDER ROUSSANOV, Life Sciences Regulatory and Privacy Lawyer, Arnold & Porter
• ROBERT A. JOHNSTONE, Board Member, International Alliance of Patients Organisations
• JOHAN DE MUNTER, Assistant Nurse Manager Cancer Center, President, University Hospital Ghent, European Oncology Nursing Society
• MARC MARTENS, Partner, Bird & Bird

KEY THEMES:

• Strategies for market access and expansion by identifying key changes and future projections
• Understanding the biosimilars opportunity for pharma companies
• Consequences of Brexit & this pandemic situation on Biosimilars
• Current Challenges and Opportunities for future- Strategies in developing Biosimilars
• A Clinician ?s Guide to Biosimilars in Oncology: understanding the Science of Extrapolation and Interchangeability
• Biosimilars – Pricing & Market access - Bringing it faster into market
• GMP, GCP, QC & R&D
• Current challenges and opportunities - strategies to develop Biosimilars
• Payer perspective on biologics and Biosimilars
• Biosimilar Interchangeability: The newest regulation
• Biosimilar - Physicians and Patients perspective
• CMC, Preclinical and clinical considerations for Biosimilars and Follow-on Biologics
• Impact of Technology
• Commercial landscape & market access for Biosimilars: Predicts to prepare for a successful tomorrow
• Hear case studies on biosimilars drug development from pre-clinical to clinical and the various testing required such as immunogenicity and bio-similarity tests
• Research-based industry Biosimilar strategies
• Considerations for the analytical similarity assessments when designing a Biosimilar development program
• Determining the right investments & potential returns from Biosimilars
• Latest developments in regulation to increase speed of entry and compliance
• Future of next generation biosimilars
• Be part of a major networking opportunity

Get more from the event, enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference. Whether you are on the branded or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway.